Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies

HIGHLIGHTS

• Who: Relapse and colleagues from the Continuous and categorical data are summarized as medians with ranges and frequencies, respectivelyOverall survival (OS) was defined as the time from transplantation to death due to any cause. Diseasefree survival (DFS) was defined as the time from transplantation to relapse or death, whichever occurred first. For patients who remained alive or disease-free, OS and DFS were censored at the date of the last follow-up. The Kaplan-Meier method was used to estimate the probabilities of OS and DFS have published the research: Azacitidine and gemtuzumab ozogamicin as post-transplant . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.